GenSight Biologics S.A. Stock price

Equities

SIGHT

FR0013183985

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:35:10 2024-03-27 pm EDT Pre-market 03:34:31 am
0.396 EUR -1.00% Intraday chart for GenSight Biologics S.A. 0.396 0.00%
Sales 2023 3M 3.24M Sales 2024 * 4.4M 4.75M Capitalization 30.93M 33.42M
Net income 2023 -26M -28.1M Net income 2024 * -26M -28.1M EV / Sales 2023 8.55 x
Net Debt 2023 * 29.4M 31.77M Net Debt 2024 * 57.8M 62.46M EV / Sales 2024 * 20.2 x
P/E ratio 2023
-0.85 x
P/E ratio 2024 *
-0.69 x
Employees 23
Yield 2023 *
-
Yield 2024 *
-
Free-Float 90.77%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on GenSight Biologics S.A.

1 day-1.00%
1 week-12.49%
1 month-0.75%
3 months-13.44%
6 months-43.02%
Current year-13.91%
More quotes
1 week
0.39
Extreme 0.39
0.45
1 month
0.38
Extreme 0.377
0.60
Current year
0.30
Extreme 0.2995
0.60
1 year
0.30
Extreme 0.2995
2.53
3 years
0.30
Extreme 0.2995
10.08
5 years
0.30
Extreme 0.2995
10.08
10 years
0.30
Extreme 0.2995
10.82
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-05-18
Director of Finance/CFO 41 15-05-31
Chief Tech/Sci/R&D Officer - 22-03-31
Members of the board TitleAgeSince
Chairman 69 13-09-30
Director/Board Member 72 14-05-31
Founder 68 11-12-31
More insiders
Date Price Change Volume
24-03-27 0.396 -1.00% 78,279
24-03-26 0.4 -0.25% 57,643
24-03-25 0.401 -10.29% 301,125
24-03-22 0.447 +1.94% 36,323
24-03-21 0.4385 -3.09% 123,647

Real-time Euronext Paris, March 27, 2024 at 12:35 pm EDT

More quotes
GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2022, the company had a portfolio of 2 products, including 1 in phase III clinical development (Lumevoq for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.396 EUR
Average target price
0.4 EUR
Spread / Average Target
+1.01%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock GenSight Biologics S.A. - Euronext Paris